Mesenchymal stem cells for the treatment of cns diseases

Patent metadata

Field	Value
Publication number	US-2016375098-A1
Application number	US-201615261959-A
Country	US
Kind code	A1
Filing date	Sep 11, 2016
Priority date	May 28, 2008
Publication date	Dec 29, 2016
Grant date	—

Abstract

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

First claim

What is claimed is:

1 . A method of treating a CNS disease or disorder comprising administering to an individual in need thereof a therapeutically effective amount of non-genetically modified human cells which express at least one mesenchymal stem cell marker and secrete brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), and do not secrete nerve growth factor (bNGF), wherein said at least one mesenchymal stem cell marker is selected from the group consisting of CD7, CD90 and CD105, wherein a basal secretion of said GDNF in the cells is at least two times greater than a basal secretion of said GDNF in non-differentiated, non-genetically modified human mesenchymal stem cells, wherein said non-genetically modified human cells are differentiated ex vivo from mesenchymal stem cells.

2 . The method of claim 1 , wherein said non-genetically modified human cells further express at least one additional neurotrophic factor.

3 . The method of claim 2 , wherein said at least one additional neurotrophic factor is selected from the group consisting of neurotrophin-3 (NT-3), neurotrophin-4/5, Neurturin (NTN), Persephin, artemin (ART), ciliary neurotrophic factor (CNTF), insulin growth factor-I (IGF-1) and Neublastin.

4 . The method of claim 1 , wherein said non-genetically modified human cells take up at least ten times more glutamate from their surroundings than non-differentiated, non-genetically modified mesenchymal stem cells.

5 . The method of claim 1 , wherein the CNS disease or disorder is a neurodegenerative disease or disorder.

6 . The method of claim 5 , wherein the CNS disease or disorder is selected from the group consisting of a motion disorder, a dissociative disorder, a mood disorder, an affective disorder, an addictive disorder and a convulsive disorder.

7 . The method of claim 5 , wherein the neurodegenerative disorder is selected from the group consisting of Parkinson's, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease and Huntingdon's disease.

8 . The method of claim 1 , wherein said non-genetically modified human cells are autologous to said subject.

9 . The method of claim 1 , wherein said non-genetically modified human cells are non-autologous to said subject.

10 . The method of claim 1 , wherein said non-genetically modified human cells are allogeneic to said subject.

11 . The method of claim 1 , wherein said administering to the subject comprises administering to the central nervous system (CNS) of the subject.

Assignees

• Ramot At Tel-Aviv Univ Ltd
• Brainstorm Cell Therapeutics Ltd

Inventors

• Kadouri Avinoam
• Bar-Ilan Avihay
• Melamed Eldad
• Offen Daniel
• Sadan Ofer
• Bahat-Stromza Merav

Classifications

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C12N2500/84

  from mammals · CPC title

• C12N5/0667

  Adipose-derived stem cells [ADSC]; Adipose stromal stem cells · CPC title

• C12N5/0664

  Dental pulp stem cells, Dental follicle stem cells · CPC title